Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Biotechnol. 2004 Jun;22(6):701-6. Epub 2004 May 9.

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.

Author information

  • 1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York 10021, USA. smith-jp@mskcc.org

Abstract

The development of therapeutic inhibitors of key signaling pathways has been hampered by the inability to assess the effect of a drug on its target in the patient. 17-allylaminogeldanamycin (17-AAG) is the first Hsp90 inhibitor to be tested in a clinical trial. It causes the degradation of HER2 and other Hsp90 targets, and has antitumor activity in preclinical models. We have developed a method for imaging the inhibition of Hsp90 by 17-AAG. We labeled an F(ab')2 fragment of the anti-HER2 antibody Herceptin with 68Ga, a positron emitter, which allows the sequential positron-emission tomographic imaging of HER2 expression. We have used this method to quantify as a function of time the loss and recovery of HER2 induced by 17-AAG in animal tumors. This approach allows noninvasive imaging of the pharmacodynamics of a targeted drug and will facilitate the rational design of combination therapy based on target inhibition.

Comment in

  • An image worth a thousand lives? [Nat Biotechnol. 2004]
PMID:
15133471
[PubMed - indexed for MEDLINE]
Free full text

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk